TREATMENT BY HEMCITABIN AND AN EPIDERMAL GROWTH FACTOR (EGFR) RECEPTOR INHIBITOR

摘要

1. A pharmaceutical composition, primarily intended for use in the treatment of cancer, comprising an epidermal growth factor receptor kinase inhibitor (EGFR) and gemcitabine in a pharmaceutically acceptable carrier. The pharmaceutical composition according to claim 1, wherein the EGFR receptor kinase inhibitor is erlotinib. The pharmaceutical composition according to claim 2, wherein erlotinib in the composition is used in the form of hydrochloride. The pharmaceutical composition according to claim 2 or 3, further comprising one or more other antitumor agents. A method for producing a medicament for the treatment of tumors or tumor metastases, which comprises an EGFR receptor kinase inhibitor and gemcitabine. 6. The method of claim 5, wherein the medicament is for treating cancer. The method of claim 5 or 6, wherein the EGFR receptor kinase inhibitor and gemcitabine are contained in the same composition. The method of claim 5 or 6, wherein the EGFR receptor kinase inhibitor and gemcitabine are contained in various compositions. The method of claim 5, wherein the EGFR receptor kinase inhibitor and gemcitabine are intended to be administered to a patient in the same manner. The method of claim 9, wherein the EGFR receptor kinase inhibitor and gemcitabine are intended to be administered to a patient in various ways. The method of claim 10, wherein erlotinib is used as an EGFR receptor kinase inhibitor. The method of claim 11, wherein erlotinib is intended for administration to a patient in a parenteral or oral manner. The method of claim 10, wherein gemcitabine is intended for administration to a patient by a parenteral route. The method of claim 5, further comprising